Prostate Cancer Medicine is Now Available for One-Third of the Price in India

Listen to this News

Highlights:

• Prostate cancer typically affects men over the age of 65 in India. However, there has been an increase in cancer reports among men aged 35-44 and 55-64, primarily in metropolitan areas
• In India, the first generic version of Apalutamide, a medicine used to treat prostate cancer, has been introduced at one-third the original price
• Apalutamide combined with androgen-deprivation treatment significantly reduced the risk of disease progression and mortality by 35%

BDR Pharmaceutical launched Apatide, the first generic of a major prostate cancer medicine - Apalutamide - in India at one-third the price of the original brand.

Pricing of Newly Launched Prostate Cancer Medicine

According to Raheel Shah, Director of Business Development, BDR Group, the medicine will be offered in India in strengths of 60mg in packs of 60 and 120 tablets. "Typically, a patient is put on this medicine for two months with a one-week break in between," Shah explained.

‘BDR Pharma�s prostate cancer medicine costs one-third the price of the original brand. A bottle of 60 tablets costs Rs 22,500, while a bottle of 120 tablets costs Rs 45,000.’

A bottle of 60 tablets costs Rs 22,500, while a bottle of 120 tablets costs Rs 45,000.

Apalutamide and Anti-Androgen Therapy for Prostate Cancer

The University of California system invented apalutamide, which was principally developed by Janssen Research & Development, a branch of Johnson & Johnson.

"Apalutamide in combination with anti-androgen therapy will significantly improve chances for survival within metastatic castration sensitive prostate cancer patients. Apalutamide plus ADT (androgen-deprivation therapy) arm shows a significant decrease in the risk of disease progression and reduces the risk of mortality by 35% amongst Non-Metastatic Castration-resistant Prostrate Cancer," the company said.

BDR Pharmaceutical's Medicines for Prostate Cancer

The voyage of BDRs for the treatment of prostate cancer began with Abiratarone Acetate, then Leuprolide Acetate, Enzalutamide, Degarelix, and Triptorelin.

Rise in Prostate Cancer Cases Globally

Because of population increase and aging, the worldwide prostate cancer burden is anticipated to rise to 1.7 million new cases and 4, 99,000 new deaths by 2030. Prostate cancer is the second most prevalent cause of cancer in India and the sixth main cause of cancer deaths among males worldwide. People's access to information about the disease is at a bare minimum, with minimal acceptance.

Source: Medindia

Cite this Article ⇣⇡

Please use one of the following formats to cite this article in your essay, paper or report:

• APA

  Dr. Trupti Shirole. (2023, January 05). Prostate Cancer Medicine is Now Available for One-Third of the Price in India. Medindia. Retrieved on Dec 26, 2024 from https://www.medindia.net/news/healthwatch/prostate-cancer-medicine-is-now-available-for-one-third-of-the-price-in-india-209945-1.htm.

• MLA

  Dr. Trupti Shirole. "Prostate Cancer Medicine is Now Available for One-Third of the Price in India". Medindia. Dec 26, 2024. <https://www.medindia.net/news/healthwatch/prostate-cancer-medicine-is-now-available-for-one-third-of-the-price-in-india-209945-1.htm>.

• Chicago

  Dr. Trupti Shirole. "Prostate Cancer Medicine is Now Available for One-Third of the Price in India". Medindia. https://www.medindia.net/news/healthwatch/prostate-cancer-medicine-is-now-available-for-one-third-of-the-price-in-india-209945-1.htm. (accessed Dec 26, 2024).

• Harvard

  Dr. Trupti Shirole. 2023. Prostate Cancer Medicine is Now Available for One-Third of the Price in India. Medindia, viewed Dec 26, 2024, https://www.medindia.net/news/healthwatch/prostate-cancer-medicine-is-now-available-for-one-third-of-the-price-in-india-209945-1.htm.